Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 185

Sort by

Sort Order Select

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao, Jeremy Eisele, Leah Gehrs, Julie K. Ritchey, Jaebok Choi, Camille N Abboud, Iskra Pusic, Meagan A Jacoby, Peter Westervelt, Matthew Christopher, Amanda F. Cashen, Armin Ghobadi, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio

Blood blood.2024026497.

https://doi.org/10.1182/blood.2024026497

Published: 2024

Includes: Supplemental data

Journal Articles

DNA Hypomethylation Is Not Sufficient to Account for Decitabine Mediated Cytotoxicity in TP53 -Mutated Myeloid Malignancies

Jeremy T. Baeten, Sumedha Agashe, Annabel Quinet, Jamie Butler, Amber C. Carter, Jack Wooldridge, Kimberly Johansson, Geoffrey L. Uy, Alessandro Vindigni, Daniel C. Link

Blood (2024) 144 (Supplement 1): 5783.

https://doi.org/10.1182/blood-2024-211001

Published: 2024

Journal Articles

Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma

Michael H. Kramer, Neha Mehta-Shah, Michael P. Rettig, Katherine Stricker, Melinda Harding, Feng Gao, Brett Ramsey, Peter Westervelt, Jan K Davidson-Moncada, Armin Ghobadi, John F. DiPersio, Geoffrey L. Uy

Blood (2024) 144 (Supplement 1): 2066.

https://doi.org/10.1182/blood-2024-200809

Published: 2024

Journal Articles

Waning Long Term Efficacy of COVID-19 Post-Transplant Vaccination for Prevention of COVID-19 Adverse Events in Transplant and Cellular Therapy (TCT) Patients

Rahul Ramaswamy, Laith Fakhoury, Peter Zhao, Ningying Wu, Feng Gao, Geoffrey L. Uy, John F. DiPersio, Zachary D. Crees

Blood (2024) 144 (Supplement 1): 3532.

https://doi.org/10.1182/blood-2024-204417

Published: 2024

Journal Articles

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Shai O. Shimony, Heardley Murdock, Julia Keating, Christopher R. Reilly, Harrison K. Tsai, Christopher J. Gibson, Stefan Faderl, Tony Wagner, Nalina Dronamraju, Tara L. Lin, Ellen K. Ritchie, Thomas Prebet, Jorge E. Cortes, Geoffrey L. Uy, Jeffrey E Lancet, Donna S. Neuberg, Richard M. Stone, R. Coleman Lindsley

Blood (2024) 144 (Supplement 1): 60.

https://doi.org/10.1182/blood-2024-200413

Published: 2024

Journal Articles

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica M. Stempel, Luca Lanino, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Stacey M. Frumm, Shougat Barua, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 664.

https://doi.org/10.1182/blood-2024-208034

Published: 2024

Journal Articles

Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

Blood (2024) 144 (Supplement 1): 736.

https://doi.org/10.1182/blood-2024-210370

Published: 2024

Journal Articles

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Blood (2024) 144 (Supplement 1): 733.

https://doi.org/10.1182/blood-2024-209097

Published: 2024

Journal Articles

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Jessica Kaplan Altman, Zhuoxin Sun, Alexander E. Perl, Richard Little, Steven D. Gore, Laura C. Michaelis, Geoffrey L. Uy, Yasmin Abaza, Sameem Abedin, John L. Reagan, Ehab L. Atallah, Selina Luger, Mark R. Litzow

Blood (2024) 144 (Supplement 1): 2907.1.

https://doi.org/10.1182/blood-2024-199701

Published: 2024

Journal Articles

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML

Blood (2024) 144 (Supplement 1): 2921.

https://doi.org/10.1182/blood-2024-210110

Published: 2024

Journal Articles

Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 1): 308.

https://doi.org/10.1182/blood-2024-209438

Published: 2024

Journal Articles

Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial

Blood (2024) 144 (Supplement 1): 779.

https://doi.org/10.1182/blood-2024-207557

Published: 2024

Journal Articles

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Blood (2024) 144 (Supplement 1): 224.

https://doi.org/10.1182/blood-2024-201694

Published: 2024

Journal Articles

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Blood (2024) 144 (Supplement 1): 4211.

https://doi.org/10.1182/blood-2024-207143

Published: 2024

Journal Articles

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Ted M. Getz, Tariq Kewan, Jan Philipp Bewersdorf, Jessica M. Stempel, Luca Lanino, Wei Wei, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Somedeb Ball, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Gail J. Roboz, Benjamin Rolles, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Justin Grenet, Zhuoer Xie, Yazan F. Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vasiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Maximilian Stahl, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 3219.

https://doi.org/10.1182/blood-2024-202075

Published: 2024

Journal Articles

Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action

Vijaya Raj Bhatt, Geoffrey L. Uy, Heidi D. Klepin

Blood (2024) 143 (6): 483–487.

https://doi.org/10.1182/blood.2023022611

Published: 2024

Includes: Supplemental data

Journal Articles

Characterization of Comparative Clinical Outcomes and Molecular Features of Black Patients with Acute Promyelocytic Leukemia (APL) Reveals Similar Survival and Distinct Genomic Profiles

Blood (2023) 142 (Supplement 1): 389.

https://doi.org/10.1182/blood-2023-182376

Published: 2023

Journal Articles

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML

Blood (2023) 142 (Supplement 1): 1575.

https://doi.org/10.1182/blood-2023-185135

Published: 2023

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P. Rettig, Feng Gao, Julie K. Ritchey, Camille N. Abboud, Iskra Pusic, Peter Westervelt, Amanda F Cashen, Matt Christopher, Armin Ghobadi, Ramzi Abboud, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio, Leah Gehrs

Blood (2023) 142 (Supplement 1): 651.

https://doi.org/10.1182/blood-2023-180289

Published: 2023

Journal Articles

Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients

Richard J Marrero, Deedra Nicolet, Vivek M. Shastri, Krzysztof Mrózek, Christopher J. Walker, William Blum, Bayard L Powell, Jonathan E Kolitz, Joseph O Moore, Geoffrey L Uy, Wendy Stock, Andrew J Carroll, John C. Byrd, Ann-Kathrin Eisfeld, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 2954.

https://doi.org/10.1182/blood-2023-187361

Published: 2023

NARROW

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

DNA Hypomethylation Is Not Sufficient to Account for Decitabine Mediated Cytotoxicity in TP53 -Mutated Myeloid Malignancies

Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma

Waning Long Term Efficacy of COVID-19 Post-Transplant Vaccination for Prevention of COVID-19 Adverse Events in Transplant and Cellular Therapy (TCT) Patients

AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML

Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action

Characterization of Comparative Clinical Outcomes and Molecular Features of Black Patients with Acute Promyelocytic Leukemia (APL) Reveals Similar Survival and Distinct Genomic Profiles

BRAF -Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only